Equities

Therapeutic Solutions International Inc

TSOI:PKC

Therapeutic Solutions International Inc

Actions
  • Price (USD)0.0008
  • Today's Change0.000 / -3.61%
  • Shares traded5.71m
  • 1 Year change-56.76%
  • Beta1.6316
Data delayed at least 15 minutes, as of Sep 20 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.

  • Revenue in USD (TTM)91.38k
  • Net income in USD-2.00m
  • Incorporated2007
  • Employees3.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Helius Medical Technologies Inc594.00k-8.84m2.61m22.00--0.4116--4.39-10.68-10.680.50421.980.06060.74864.4827,000.00-90.17-98.37-110.33-143.5712.7937.27-1,487.54-1,580.663.80--0.00---18.176.1437.11---41.95--
Invo Bioscience Inc5.77m-7.08m2.72m25.00------0.4706-3.24-3.242.440.35290.467712.0034.74230,781.20-57.44-94.63-116.03-151.4544.8974.91-122.80-343.110.2686-4.750.6588--267.3843.6226.24--87.09--
Heart Test Laboratories Inc18.60k-7.29m2.73m15.00--0.4568--146.82-5.65-5.650.00116.550.00350.0092--1,240.00-135.14---193.38--67.31---39,193.76--4.02-20.720.0777--261.17---3.95------
Acutus Medical Inc9.55m-9.70m2.97m233.00------0.3113-0.33010.09560.3261-0.13530.12111.141.4640,974.25-12.30-46.76-14.84-56.88-24.07-89.12-101.56-773.492.89-4.641.13--136.3627.03-141.35---35.99--
Tenon Medical Inc3.37m-13.87m3.09m21.00------0.9169-39.79-39.799.451.760.42522.275.27160,571.40-174.87---495.99--60.32---411.27--1.02--0.00--323.73--17.63------
ReShape Lifesciences Inc8.05m-9.02m3.29m31.00--1.08--0.4091-1.29-1.290.47660.10330.8820.80354.79259,548.40-98.88-136.06-169.55-194.3267.4756.30-112.11-408.360.8875--0.00---22.79-0.947475.36---49.29--
Fuse Medical Inc18.40m3.63m3.40m31.001.28--0.92160.18470.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Therapeutic Solutions International Inc91.38k-2.00m3.91m3.00--2.84--42.76-0.0005-0.00050.000020.00030.02521.295.2430,460.00-63.67-162.32-153.29--65.1867.79-2,530.31-2,391.850.3883-6.940.3164---52.1395.3543.11------
Kelyniam Global Inc517.70k-420.28k3.94m0.00--7.27--7.60-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
Nu-Med Plus Inc0.00-112.13k4.18m2.00---------0.0014-0.00140.00-0.00220.00----0.00-471.23-447.69---------------21.34--------3.56------
AccuStem Sciences Inc0.00-1.65m4.43m3.00---------0.1454-0.14540.00-0.25420.00----0.00-551.46--------------------------45.26------
Encision Inc6.56m-529.29k4.63m22.00--2.49--0.7056-0.045-0.0450.5560.15661.702.107.59298,337.30-13.69-3.03-19.50-4.1349.0051.25-8.06-1.891.01-8.890.1761---10.38-5.64-113.55---9.54--
Biomerica Inc5.41m-5.98m4.72m63.00--0.7162--0.872-0.3554-0.35540.32180.39180.45662.176.4985,920.63-50.43-44.68-61.13-51.7311.2314.11-110.44-63.822.43--0.00--1.420.810916.27---7.64--
Aethlon Medical, Inc.0.00-11.50m4.99m14.00--0.5727-----3.87-3.870.000.62510.00----0.00-84.49-76.25-98.84-85.78-------2,246.87----0.00---100.00---1.43------
ADM Tronics Unlimited Inc3.06m-472.80k5.07m7.00--4.97--1.66-0.007-0.0070.04530.01511.113.725.67---17.14-15.22-29.35-22.0942.8741.15-15.45-18.580.8954--0.3259---19.35-0.3572-810.74------
Data as of Sep 20 2024. Currency figures normalised to Therapeutic Solutions International Inc's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Strategic Investment Solutions, Inc. (Illinois)as of 30 Jun 20240.000.00%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.